In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts
Maya Sreeranganathan,1 Saji Uthaman,2 Bruno Sarmento,3–5 Chethampadi Gopi Mohan,1 In-Kyu Park,1 Rangasamy Jayakumar2 1Centre for Nanosciences and Molecular Medicine, Amrita University, Kochi, India; 2Department of Biomedical Science, BK21 PLUS Center for Creative Biomedical Scientists, Ch...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d367c04d73b74ff1b2ac899b99ef33aa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d367c04d73b74ff1b2ac899b99ef33aa |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d367c04d73b74ff1b2ac899b99ef33aa2021-12-02T02:28:07ZIn vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts1178-2013https://doaj.org/article/d367c04d73b74ff1b2ac899b99ef33aa2017-09-01T00:00:00Zhttps://www.dovepress.com/in-vivo-evaluation-of-cetuximab-conjugated-polygamma-glutamic-acid-doc-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Maya Sreeranganathan,1 Saji Uthaman,2 Bruno Sarmento,3–5 Chethampadi Gopi Mohan,1 In-Kyu Park,1 Rangasamy Jayakumar2 1Centre for Nanosciences and Molecular Medicine, Amrita University, Kochi, India; 2Department of Biomedical Science, BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Gwangju, Republic of Korea; 3I3S – Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal, 4INEB – Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal, 5CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra, Portugal Abstract: Epidermal growth factor receptor (EGFR), upregulated in gastric cancer patients, is an oncogene of interest in the development of targeted cancer nanomedicines. This study demonstrates in silico modeling of monoclonal antibody cetuximab (CET MAb)-conjugated docetaxel (DOCT)-loaded poly(γ-glutamic acid) (γ-PGA) nanoparticles (Nps) and evaluates the in vitro/in vivo effects on EGFR-overexpressing gastric cancer cells (MKN-28). Nontargeted DOCT-γ-PGA Nps (NT Nps: 110±40 nm) and targeted CET MAb-DOCT-γ-PGA Nps (T Nps: 200±20 nm) were prepared using ionic gelation followed by 1-Ethyl-3-(3-dimethyl aminopropyl)carbodiimide­– N-Hydoxysuccinimide (EDC­– NSH) chemistry. Increased uptake correlated with enhanced cytotoxicity induced by targeted Nps to EGFR +ve MKN-28 compared with nontargeted Nps as evident from MTT and flow cytometric assays. Nanoformulated DOCT showed a superior pharmacokinetic profile to that of free DOCT in Swiss albino mice, indicating the possibility of improved therapeutic effect in the disease model. Qualitative in vivo imaging showed early and enhanced tumor targeted accumulation of CET MAb-DOCT-γ-PGA Nps in EGFR +ve MKN-28–based gastric cancer xenograft, which exhibited efficient arrest of tumor growth compared with nontargeted Nps and free DOCT. Thus, actively targeted CET MAb-DOCT-γ-PGA Nps could be developed as a substitute to conventional nonspecific chemotherapy, and hence could become a feasible strategy for cancer therapy for EGFR-overexpressing gastric tumors. Keywords: targeted nanoparticles, poly(γ-glutamic acid) nanoparticles, docetaxel, cetuximab, epidermal growth factor receptor, gastric cancerSreeranganathan MUthaman SSarmento BMohan CGPark IKJayakumar RDove Medical PressarticleTargeted nanoparticlesPoly (-glutamic acid) nanoparticlesDocetaxelCetuximabEpidermal Growth Factor ReceptorGastric cancer.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 7165-7182 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Targeted nanoparticles Poly (-glutamic acid) nanoparticles Docetaxel Cetuximab Epidermal Growth Factor Receptor Gastric cancer. Medicine (General) R5-920 |
| spellingShingle |
Targeted nanoparticles Poly (-glutamic acid) nanoparticles Docetaxel Cetuximab Epidermal Growth Factor Receptor Gastric cancer. Medicine (General) R5-920 Sreeranganathan M Uthaman S Sarmento B Mohan CG Park IK Jayakumar R In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts |
| description |
Maya Sreeranganathan,1 Saji Uthaman,2 Bruno Sarmento,3–5 Chethampadi Gopi Mohan,1 In-Kyu Park,1 Rangasamy Jayakumar2 1Centre for Nanosciences and Molecular Medicine, Amrita University, Kochi, India; 2Department of Biomedical Science, BK21 PLUS Center for Creative Biomedical Scientists, Chonnam National University Medical School, Gwangju, Republic of Korea; 3I3S – Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal, 4INEB – Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal, 5CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Instituto Universitário de Ciências da Saúde, Gandra, Portugal Abstract: Epidermal growth factor receptor (EGFR), upregulated in gastric cancer patients, is an oncogene of interest in the development of targeted cancer nanomedicines. This study demonstrates in silico modeling of monoclonal antibody cetuximab (CET MAb)-conjugated docetaxel (DOCT)-loaded poly(γ-glutamic acid) (γ-PGA) nanoparticles (Nps) and evaluates the in vitro/in vivo effects on EGFR-overexpressing gastric cancer cells (MKN-28). Nontargeted DOCT-γ-PGA Nps (NT Nps: 110±40 nm) and targeted CET MAb-DOCT-γ-PGA Nps (T Nps: 200±20 nm) were prepared using ionic gelation followed by 1-Ethyl-3-(3-dimethyl aminopropyl)carbodiimide­– N-Hydoxysuccinimide (EDC­– NSH) chemistry. Increased uptake correlated with enhanced cytotoxicity induced by targeted Nps to EGFR +ve MKN-28 compared with nontargeted Nps as evident from MTT and flow cytometric assays. Nanoformulated DOCT showed a superior pharmacokinetic profile to that of free DOCT in Swiss albino mice, indicating the possibility of improved therapeutic effect in the disease model. Qualitative in vivo imaging showed early and enhanced tumor targeted accumulation of CET MAb-DOCT-γ-PGA Nps in EGFR +ve MKN-28–based gastric cancer xenograft, which exhibited efficient arrest of tumor growth compared with nontargeted Nps and free DOCT. Thus, actively targeted CET MAb-DOCT-γ-PGA Nps could be developed as a substitute to conventional nonspecific chemotherapy, and hence could become a feasible strategy for cancer therapy for EGFR-overexpressing gastric tumors. Keywords: targeted nanoparticles, poly(γ-glutamic acid) nanoparticles, docetaxel, cetuximab, epidermal growth factor receptor, gastric cancer |
| format |
article |
| author |
Sreeranganathan M Uthaman S Sarmento B Mohan CG Park IK Jayakumar R |
| author_facet |
Sreeranganathan M Uthaman S Sarmento B Mohan CG Park IK Jayakumar R |
| author_sort |
Sreeranganathan M |
| title |
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts |
| title_short |
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts |
| title_full |
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts |
| title_fullStr |
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts |
| title_full_unstemmed |
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts |
| title_sort |
in vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in egfr-overexpressing gastric cancer xenografts |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/d367c04d73b74ff1b2ac899b99ef33aa |
| work_keys_str_mv |
AT sreeranganathanm invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenografts AT uthamans invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenografts AT sarmentob invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenografts AT mohancg invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenografts AT parkik invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenografts AT jayakumarr invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenografts |
| _version_ |
1718402496973504512 |